FierceBiotech
  • FierceBiotech
  • FierceBiotechIT
  • FierceBiotechResearch
  • FierceBiomarkers
  • FierceDrugDelivery
  • FierceMedicalDevices
  • FierceVaccines
  • FiercePharma
  • FiercePharmaManufacturing
  • FierceCRO
  • More Fierce Network sites
  • Select another site
  • Advertise
  • Contact

Free Daily Biotech Industry Newsletter Get the latest on Biotech & Pharma Deals, Clinical Trials, FDA Decisions, and Key Regulatory Issues sent straight to your Inbox. Join over 100,000 biotech professionals who subscribe to FierceBiotech for FREE! Click here to see a sample.

FierceBiotech

  • News
  • TOPICS
    • Biosimilars
    • Chutes and Ladders
    • Clinical Trials
    • Drug Safety
    • Emerging Markets
    • Europe
    • M&A
    • Outsourcing
    • Partnering
    • Personalized Medicine
    • Pipeline
    • R&D
    • Regulatory
  • ANALYSIS
    • Third Rock's Levin calls for teamwork in personalized medicine
      by Damian Garde
    • Readers' picks, responses to Fierce's 'Top 10' cancer drugs report
      by Ryan McBride
    • More commentary
  • FEATURES
    • The Biggest R&D Spenders in Biotech
    • The Biggest R&D Spenders In Biopharma
    • Top 10 Late-Stage Cancer Drugs – 2012
  • LIBRARY
    • Webinars
    • View All
  • EVENTS
  • JOBS
    • Browse Jobs
    • Post a Job
  • Marketplace
  • Susbscribe
  • Twitter
  • Mobile
Follow US
Tag:

Decision Resources

Latest Headlines

Latest Headlines

Docs wary of any biosimilars that lack compelling data

August 24, 2011
One of the critical measures for the potential success of any new drug is how quickly specialists will start prescribing them. So analysts for Decision Resources turned to several groups to check

Related Tags

  • United Kingdom
  • Humira
  • Enbrel
  • atrial fibrillation

Decision Resources Press Releases

  • Launch of New Agents with Niche Roles Will Contribute to Drug Market Growth in the Treatment of Non-Muscle-Invasive Bladde
  • Surveyed U.S. Cardiologists Indicate That They Would Prescribe Cardiome/Merck’s Oral Vernakalant and Gilead/Menarini’s Ran
  • Linaclotide Will Become the New Market Leader and Achieve Blockbuster Status by 2018 for the Treatment of Irritable Bowel
  • For the Treatment of Type 2 Diabetes, the Vast Majority of Surveyed Physicians in China and South Korea Indicate That Ther
  • Russia’s Non-Small-Cell Lung Cancer Drug Market Will Grow to $163 Million in 2015

Join 100,000+ Insiders SIGN UP FOR OUR NEWSLETTER

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

MORE ITEMS

EVENTS

  • MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
  • Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
  • What's your BIO?June 18-21, 2012 — Boston, MA
MORE EVENTS

Press Releases

  • Chronic Pain Is Relieved by Cell Transplantation in Lab Study
  • Drug-vaccine combo better for breast cancer
  • Marked for destruction: Newly developed compound triggers cancer cell death
  • Orthofix International Completes Divestiture of Sports Medicine Business Unit
  • ConforMIS iTotal CR Knee Replacement System Wins Silver in 2012 Medical Design Excellence Awards
  • More Press Releases

Featured Jobs

  • Research & Development Chemist
    C3 Jian - Marina Del Rey, CA
  • Director, Safety Pharmacology and Toxicology
    Tesaro - Waltham, MA
  • Senior Manager, Global Market Insights Job
    Celgene Corporation - Summit, NJ, US
  • Program Lead - Scientific Information Architecture & Search
    Merck - Kenilworth, NJ
  • Sr. Director/Executive Director of Operations, Inflammation and Immunology CRD Job
    Celgene Corporation - Tokyo, Ja, US

A publication of FierceMarkets

FierceBiotech monitors biotech & pharma deals, FDA decisions, clinical trials, and more. Join more than 100,000 biotech industry leaders who subscribe to our free daily email. Click here to get your free weekly email briefing today!

The FierceMarkets Network:

Telecom
  • FierceWireless
  • FierceBroadbandWireless
  • FierceMobileContent
  • FierceDeveloper
  • FierceWireless:Europe
  • FierceTelecom
  • FierceEnterpriseCommunications
  • FierceIPTV
  • FierceOnlineVideo
  • FierceCable
Healthcare
  • FierceHealthcare
  • FiercePracticeManagement
  • FierceHealthIT
  • FierceHealthFinance
  • Hospital Impact
  • FierceEMR
  • FierceMobileHealthcare
  • FierceHealthPayer
Government
  • FierceGovernment
  • FierceGovernmentIT
  • FierceHomelandSecurity
Energy
  • FierceEnergy
  • FierceSmartGrid
Life Sciences
  • FierceBiotech
  • FierceBiotechResearch
  • FiercePharma
  • FierceVaccines
  • FierceBiotechIT
  • FiercePharmaManufacturing
  • FierceMedicalDevices
  • FierceDrugDelivery
  • FierceBiomarkers
  • FierceCRO
Enterprise IT
  • FierceCIO
  • FierceCIO:TechWatch
  • FierceMobileIT
  • FierceContentManagement
Finance
  • FierceFinance
  • FierceComplianceIT
  • FierceFinanceIT
  • Home
  • Subscribe
  • Advertise
  • Mobile Edition
  • RSS
  • Privacy
  • Editors
© 2012 FierceMarkets. All rights reserved.